MxD has been awarded funding from the Food and Drug Administration (FDA) Office of Counterterrorism and Emerging Threats (OCET) to identify the unique barriers and advantages of digital transformation in regulated medical product manufacturing.
Even prior to the pandemic’s disruptive effects, manufacturers of medical products were under increasing pressure to improve output, quality, and efficiency. While all organizations face challenges in adopting new technologies, those that operate within the framework of FDA regulation have unique constraints—and opportunities.
Now, accelerating the adoption of these new technologies is more critical than ever to address the need to rapidly respond to novel threats and become more resilient.
“All companies face an imperative to use technology to better respond to the unique demands of the time. Reaping the benefits of advanced analytics, digital twins, proactive simulation, and other emerging tools will require navigating this landscape while maintaining the highest standards for safety and efficacy,” said Chandra Brown, CEO of MxD. “Partnering with the FDA will allow MxD to identify the ideal path to digital transformation for critical subsectors including medical device, PPE, therapeutic, diagnostic, and medical product supply chain.”